Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources, which are used in cosmeceutical products, such as oat beta glucan and avenanthramides, and is being developed as potential nutraceuticals and/or pharmaceuticals. Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-1.


TSX:AEZS - Post by User

Aeterna Zentaris Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by plovieon Apr 01, 2007 3:10pm
96 Views
Post# 12527890

Palnic

PalnicWhy did you not mention the shares bought? Mar 30/07 Mar 28/07 MacDonald, Pierre 10 - Acquisition in the public market Common Shares 10,000 $4.490 Mar 30/07 Mar 28/07 Laurin, Pierre 10 - Acquisition in the public market Common Shares 1,000 $4.490 Mar 30/07 Mar 23/07 Gagnon, Gilles 97 - Other Options -60,000 $4.650 Mar 29/07 Mar 28/07 Laurin, Pierre 10 - Acquisition in the public market Common Shares 10,000 $4.490 Mar 29/07 Mar 23/07 Mazzo, David 50 - Grant of options Options 400,000 $3.540 USD Mar 29/07 Mar 23/07 Mazzo, David 00 - Opening Balance-Initial SEDI Report Options Mar 29/07 Mar 28/07 Dupont, Éric 10 - Acquisition in the public market Common Shares 5,000 $4.470 Mar 29/07 Mar 28/07 Dupont, Éric 10 - Acquisition in the public market Common Shares 5,000 $4.450
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities